Form 8-K ReWalk Robotics Ltd. For: Aug 09

 

 

ReWalk Robotics Reports Second Quarter 2021 Financial Results

 

— Second Quarter 2021 Total Revenue of $1.4 million —

— Second quarter 2021 marks the fourth consecutive quarter over quarter growth —

— Strong balance sheet with $ 64.2 million in cash, as of June 30, 2021—

MARLBOROUGH, Mass., BERLIN, Germany and YOKNEAM ILIT, Israel, August 9, 2021 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and six months ended June 30, 2021.

•

Total revenue in the second quarter of 2021 was $1.4 million;

•

Second quarter 2021 marks the fourth consecutive quarter over quarter growth;

•

Gross margin was 51% in the second quarter of 2021;

•

Total operating expenses were $3.9 million in the second quarter of 2021;

•

Cash position remains strong with $64.2 million;

•

Additional five BKK partners have joined the operating contract in Germany and

•

Jeannine Lynch will join the Company as its VP of strategy and market access on August 31, 2021.

“The second quarter results reflect the ongoing reopening of the markets. We are now able to trial many new individuals who had been waiting and filled our pipeline during the pandemic”, said Larry Jasinski, ReWalk’s Chief Executive Officer. “Our focus on achieving broader coverage in Europe and the US has also been encouraging. We are expanding our resources in order to achieve these goals and to have a market leading and experienced team for implementation as they occur.”

 

About ReWalk Robotics Ltd.

 

 

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States.

 

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: the adverse effect that the COVID-19 pandemic has had and may continue to have on the Company's business and results of operations; ReWalk's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; ReWalk's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to improve its products and develop new products; ReWalk's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential regulatory developments with respect to its mandatory 522 postmarket surveillance study; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; ReWalk's ability to establish a pathway to commercialize its products in China; the impact of substantial sales of the Company's shares by certain shareholders on the market price of the Company's ordinary shares; ReWalk's ability to use effectively the proceeds of its offerings of securities; the risk of substantial dilution resulting from the periodic issuances of ReWalk's ordinary shares; the impact of the market price of the Company's ordinary shares on the determination of whether it is a passive foreign investment company; the market and other conditions; and other factors discussed under the heading "Risk Factors" in ReWalk's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

Non-GAAP Financial Measures

 

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.

 

For the three and six months ended June 30, 2021, and 2020, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) depreciation.

 

Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation, and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in ReWalk’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.

 

The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.

 

Investor Contact:
Ori Gon

Chief Financial Officer 
ReWalk Robotics Ltd.
T: +972-4-9590123 
E: [email protected]

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2021				2020				2021				2020
Revenue		$	1,436			$	1,668			$	2,752			$	2,428
Cost of revenues			709				646				1,318				1,033
Gross profit			727				1,022				1,434				1,395
Operating expenses:
Research and development			810				954				1,605				1,939
Sales and marketing			1,613				1,353				3,284				3,034
General and administrative			1,445				1,267				2,707				2,576
Total operating expenses			3,868				3,574				7,596				7,549
Operating loss			(3,141	)			(2,552	)			(6,162	)			(6,154	)
Financial expenses (income), net			(9	)			235				(13	)			481
Loss before income taxes			(3,132	)			(2,787	)			(6,149	)			(6,635	)
Taxes on income			9				68				54				60
Net loss		$	(3,141	)		$	(2,855	)		$	(6,203	)		$	(6,695	)
Net loss per ordinary share, basic and diluted		$	(0.07	)		$	(0.22	)		$	(0.15	)		$	(0.57	)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted			46,123,222				13,101,275				41,210,527				11,744,275
Reconciliation of GAAP to Non-GAAP net loss
Net loss		$	(3,141	)		$	(2,855	)		$	(6,203	)		$	(6,695	)
Non-cash share based compensation expense			200				113				368				312
Depreciation of property and equipment, net			71				76				141				151
Non-GAAP net loss		$	(2,870	)		$	(2,666	)		$	(5,694	)		$	(6,232	)

		June 30,				December 31,
		2021				2020
		(unaudited)
Assets
Current assets
Cash and cash equivalents		$	64,236			$	20,350
Trade receivable, net			779				684
Prepaid expenses and other current assets			834				672
Inventories			3,346				3,542
Total current assets			69,195				25,248
Restricted cash and other long term assets			1,039				1,033
Operating lease right-of-use assets			1,116				1,349
Property and equipment, net			355				437
Total assets		$	71,705			$	28,067
Liabilities and equity
Current liabilities
Current maturities of operating leases			640				660
Trade payables			2,080				2,268
Other current liabilities			1,482				1,740
Total current liabilities			4,202				4,668
Noncurrent operating leases			662				923
Other long-term liabilities			763				702
Shareholders’ equity			66,078				21,774
Total liabilities and equity		$	71,705			$	28,067

		Six Months Ended
		June 30,
		2021				2020
Net cash used in operating activities		$	(6,340	)		$	(7,533	)
Net cash used in investing activities			(11	)			(15	)
Net cash provided by financing activities			50,236				5,303
Increase (decrease) in cash, cash equivalents, and restricted cash			43,885				(2,245	)
Cash, cash equivalents, and restricted cash at beginning of period			21,054				16,992
Cash, cash equivalents, and restricted cash at end of period		$	64,939			$	14,747

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2021				2020				2021				2020
Revenue:
United States		$	654			$	631			$	1,130			$	847
Europe			726				1,035				1,563				1,577
Asia Pacific			55				2				57				4
Africa			1				-				2				-
Total Revenue		$	1,436			$	1,668			$	2,752			$	2,428
Revenue:
Personal units revenue		$	1,153			$	1,667			$	2,461			$	2,381
Rehabilitation units revenue			283				1				291				47
Total Revenue		$	1,436			$	1,668			$	2,752			$	2,428